by Jakub Jarolím, Business Intelligence Department
Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).
SOTIO Biotech
27/2/2022
January 2022 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions
Market
Stocks had a lousy start to the year, but Wall Street expects good times ahead
Stocks had a lousy start to the year, and even though January is considered as the whole year’s barometer, Wall Street expects good times ahead.
Antibody-Drug Conjugates
Sutro announced positive Phase 1 results of its STRO-002 ADC in ovarian cancer
RemeGen said China’s FDA expanded the label of ADC disitamab vedotin by granting conditional approval to treat HER2-expressing, locally advanced or metastatic urothelial carcinoma.
The agency had already granted the ADC conditional approval in June 2021 for gastric cancer. Seagen paid $200 million upfront in August to obtain most global rights to disitamab vedotin, which the partners believe uses a mAb with higher HER2 affinity than Herceptin trastuzumab.
Interleukin-15 and Interleukin-2
Stock of Cue fell after posting negative early combo data of its IL-2 with Keytruda in HNC
ImmunityBio announced promising results for HIV cure strategy with Anktiva therapy
Cell Therapies
EMA recommended use of Breyanzi CAR-T therapy in patients with DLBCL
The EMA’s Committee for Medicinal Products for Human Use’s scientific committee recommended Breyanzi (lisocabtagene maraleucel) CAR T-cell therapy can be used to treat adults with DLBCL, primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B).
Other Innovative Treatment Areas
BeiGene’s Tislelizumab meets its endpoint in Phase 3 in gastric cancer
Tislelizumab from BeiGene met its primary endpoint of overall survival in a Phase 3 trial to treat patients with locally advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma also being treated with chemotherapy.
Sdílet na sociálních sítích